Ceritinib and alectinib were both second generation of ALK inhibitors that approved as first-treatment for ALK+ NSCLC. Ceritinib is initially approved at the recommended dose of 750 mg/day fasted (ceritinib 750-mg fasted). Ceritinib at a dose of 450 mg with food (ceritinib 450-mg fed) compared to ceritinib 750-mg fasted showed consistent efficacy and less gastrointestinal toxicity in the Ascend 8 trial. Although a previous cross-study indirect study compared the efficacy of ceritinib 750-mg fasted with alectinib, the efficacy of ceritinib 450-mg fed compared with alectinib is unknown. Progression-free survival of ceritinib 450-mg fed was indirectly compared with that of alectinib using a Bucher anchor-based indirect comparison approach using ceritinib 750-mg fasted as the common anchor. The comparative efficacy of alectinib vs ceritinib 750-mg fasted was obtained from matching-adjusted indirect comparison(MAIC) and the comparative efficacy of ceritinib 450-mg fed vs ceritinib 750-mg fa..... READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.2287
Authors: F. Liang, D. Shen
